These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30663129)

  • 1. Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.
    Taher AT; Origa R; Perrotta S; Kouraklis A; Belhoul K; Huang V; Han J; Bruederle A; Bobbili P; Duh MS; Porter JB
    Am J Hematol; 2019 Apr; 94(4):E96-E99. PubMed ID: 30663129
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
    Taher AT; Origa R; Perrotta S; Kouraklis A; Ruffo GB; Kattamis A; Goh AS; Huang V; Zia A; Herranz RM; Porter JB
    Health Qual Life Outcomes; 2018 Nov; 16(1):216. PubMed ID: 30453981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
    Kattamis A; Aydinok Y; Taher A
    Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
    Taher AT; Origa R; Perrotta S; Kourakli A; Ruffo GB; Kattamis A; Goh AS; Cortoos A; Huang V; Weill M; Merino Herranz R; Porter JB
    Am J Hematol; 2017 May; 92(5):420-428. PubMed ID: 28142202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study.
    Taher AT; Weber S; Han J; Bruederle A; Porter JB
    Am J Hematol; 2019 Jan; 94(1):E15-E17. PubMed ID: 30346059
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.
    Piolatto A; Berchialla P; Allegra S; De Francia S; Ferrero GB; Piga A; Longo F
    Sci Rep; 2021 Jun; 11(1):12581. PubMed ID: 34131221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.
    Fraser J; Brook R; He T; Lewis D
    BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32646935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
    Antmen B; Karakaş Z; Yeşilipek MA; Küpesiz OA; Şaşmaz İ; Uygun V; Kurtoğlu E; Oktay G; Aydogan G; Akın M; Salcioglu Z; Vergin C; Kazancı EG; Ünal S; Çalışkan Ü; Aral YZ; Türkkan E; Meral Güneş A; Tunç B; Gümrük F; Ayhan AC; Söker M; Koç A; Oymak Y; Ertem M; Timur Ç; Yıldırmak Y; İrken G; Apak H; Biner B; Eren TG; Işık Balcı Y; Koçak Ü; Karasu G; Akkaynak D; Patıroğlu T
    Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transitioning Patients With Iron Overload From Exjade to Jadenu.
    Tinsley SM; Hoehner-Cooper CM
    J Infus Nurs; 2018; 41(3):171-175. PubMed ID: 29659464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
    Cheng WY; Said Q; Hao Y; Xiao Y; Vekeman F; Bobbili P; Duh MS; Nandal S; Blinder M
    Curr Med Res Opin; 2018 Nov; 34(11):1959-1966. PubMed ID: 29701080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
    Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M
    J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from dispersible to film coated tablet formulation of deferasirox improves hemoglobin levels and transfusional interval in patients with transfusion-dependent-thalassemia.
    Quarta A; Sgherza N; Pasanisi A; Solfrizzi MP; Serra M; Vitucci A; Dello Iacono N; Renni R; Daprile C; Mosna F; Palma A; Frappampina R; Visceglie D; Pastore D
    Br J Haematol; 2020 Apr; 189(2):e60-e63. PubMed ID: 32119115
    [No Abstract]   [Full Text] [Related]  

  • 13. Delineating parameters of iron overload in MDS patients treated with deferasirox.
    Leitch HA
    Leuk Res; 2010 Dec; 34(12):1556-7. PubMed ID: 20719382
    [No Abstract]   [Full Text] [Related]  

  • 14. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy Of Interrupted And Modified Deferasirox Dose Among Paediatric Patients With Β- Thalassemia Major And High Alanine Aminotransferase Level.
    Al Hafidh NM
    J Ayub Med Coll Abbottabad; 2019; 31(2):182-184. PubMed ID: 31094112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of new film-coated tablet formulation of deferasirox vs deferoxamine among major beta-thalassemia patients in Iran.
    Saiyarsarai P; Khorasani E; Photogeraphy H; Ghaffari Darab M; Seyedifar M
    Medicine (Baltimore); 2020 Jul; 99(28):e20949. PubMed ID: 32664096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome.
    Polat AK; Belli AA; Karakus V; Dere Y
    An Bras Dermatol; 2017; 92(5 Suppl 1):59-61. PubMed ID: 29267448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study.
    Tartaglione I; Origa R; Kattamis A; Pfeilstöcker M; Gunes S; Crowe S; Fagan N; Vincenzi B; Ruffo GB
    Exp Hematol Oncol; 2020; 9():20. PubMed ID: 32793403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
    Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
    Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersensitivity Myocarditis Following Deferasirox Administration.
    Frustaci A; Verardo R; Labbadia G; Menafra V; Galea N; Antonio Russo M
    Circ Cardiovasc Imaging; 2022 Feb; 15(2):e013702. PubMed ID: 35094520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.